AAIC 2025 Abstract
Early Disclosure of Blood‐Based Biomarkers Optimizes Alzheimer's Disease Management and Treatment Initiation: the PLASMAR study
By Isabel Estragués-Gázquez, José Contador, Leidy Dayana Martinez, Show 16 more authorsMarc Suárez-Calvet
Trial in peopleInterventions
Abstract
Background: Blood‐based biomarkers (BBMs) offer a cost‐effective, non‐invasive approach for detecting Alzheimer's disease (AD) pathology, but their impact on improving diagnostic certainty and patient management remains unclear.
